The Pharmaceutical Research Center (PRC) is responsible for the safe and ethical provision of investigational/study medications to research subjects enrolled in clinical drug trials within the University of Wisconsin Hospital and Clinics (UWHC) and the University of Wisconsin Carbone Cancer Center (UWCCC). The PRC service ensures that drug research protocols proceed optimally through UWHC's established medication use system and in accordance with all federal, state, institutional and sponsor regulations governing clinical research. While the PRC program supports all UW-Madison investigators conducting clinical drug research, its relationship with UWCCC is unique in its level of commitment, the breadth and depth of services provided and its expertise in handling biohazardous and gene therapy products. The PRC provides detailed protocol review and feasibility assessment within the confines of an academic medical center. It ensures full compliance with federal, state, sponsor and institutional requirements through activities such as;establishment of drug handling/distribution/preparation/destruction procedures;creation of investigational drug monographs for health care providers;education of healthcare staff regarding protocol procedures;creation of preprinted physician orders and prescriptions;drug inventory management and accountability;drug preparation and/or oversight;quality assurance audits;and protocol amendment management. It operates satellite pharmacy locations, optimizing ability to extend clinical research into the community. The services are continually refined and expanded to meet the evolving needs of UWCCC research faculty, research infrastructure and the research subject.

Public Health Relevance

The Pharmaceutical Research Center is responsible for the safe and ethical provision of study medications to research subjects enrolled in clinical drug trials within the University of Wisconsin Hospital and Clinics and the University of Wisconsin Carbone Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014520-40
Application #
8762767
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
40
Fiscal Year
2014
Total Cost
$111,438
Indirect Cost
$59,444
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Chute, Colleen; Yang, Xinhai; Meyer, Kristy et al. (2018) Syndecan-1 induction in lung microenvironment supports the establishment of breast tumor metastases. Breast Cancer Res 20:66
Farnoodian, Mitra; Sorenson, Christine M; Sheibani, Nader (2018) Negative Regulators of Angiogenesis, Ocular Vascular Homeostasis, and Pathogenesis and Treatment of Exudative AMD. J Ophthalmic Vis Res 13:470-486
Nayak, Amruta P; Kapur, Arvinder; Barroilhet, Lisa et al. (2018) Oxidative Phosphorylation: A Target for Novel Therapeutic Strategies Against Ovarian Cancer. Cancers (Basel) 10:
Litzelman, Kristin; Keller, Abiola O; Tevaarwerk, Amye et al. (2018) Adequacy of Depression Treatment in Spouses of Cancer Survivors: Findings From a Nationally Representative US Survey. J Gen Intern Med 33:869-876
Gurel, Zafer; Sheibani, Nader (2018) O-Linked ?-N-acetylglucosamine (O-GlcNAc) modification: a new pathway to decode pathogenesis of diabetic retinopathy. Clin Sci (Lond) 132:185-198
Li, Chao; Yu, Jiaquan; Paine, Paxton et al. (2018) Double-exclusive liquid repellency (double-ELR): an enabling technology for rare phenotype analysis. Lab Chip 18:2710-2719
Braun, Rudolf K; Chetty, Chandramu; Balasubramaniam, Vivek et al. (2018) Intraperitoneal injection of MSC-derived exosomes prevent experimental bronchopulmonary dysplasia. Biochem Biophys Res Commun 503:2653-2658
Gangnon, Ronald E; Stout, Natasha K; Alagoz, Oguzhan et al. (2018) Contribution of Breast Cancer to Overall Mortality for US Women. Med Decis Making 38:24S-31S
Turk, Anita A; Wisinski, Kari B (2018) PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. Cancer 124:2498-2506
Liu, Ting; Shi, Changzheng; Duan, Linqi et al. (2018) A highly hemocompatible erythrocyte membrane-coated ultrasmall selenium nanosystem for simultaneous cancer radiosensitization and precise antiangiogenesis. J Mater Chem B 6:4756-4764

Showing the most recent 10 out of 1528 publications